All evidence | National Institute for Health and Care Excellence - NICE, British National Formulary for Children - BNFc, Royal College of Psychiatrists - RCPsych, Brain Tumour Charity, Arthritis Research UK, Canadian Paediatric Society, European Society of Gastrointestinal Endoscopy | Medicines Current Awareness | Search results page 1 | Evidence search

Add this result to my export selection

Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) - guidance (TA662)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

25 November 2020

NICE is unable to make a recommendation on durvalumab (Imfinzi) in combination for untreated extensive-stage small-cell lung cancer in adults because AstraZenec

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer - guidance (TA660)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

25 November 2020

Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura - guidance (TA667)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

16 December 2020

Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma - guidance (TA666)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

16 December 2020

Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia - guidance (TA663)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

09 December 2020

Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Liraglutide for managing overweight and obesity - guidance (TA664)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

09 December 2020

Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma - guidance (TA661)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

25 November 2020

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in a

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Upadacitinib for treating severe rheumatoid arthritis - guidance (TA665)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

09 December 2020

Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer - guidance (TA668)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

06 January 2021

Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies - guidance (TA669)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

27 January 2021

Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adult

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Search results

Filter

Evidence type

Area of interest

Source

Filter by Date

Accredited

87 results for All evidence

Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) - guidance (TA662)

Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer - guidance (TA660)

Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura - guidance (TA667)

Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma - guidance (TA666)

Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia - guidance (TA663)

Liraglutide for managing overweight and obesity - guidance (TA664)

Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma - guidance (TA661)

Upadacitinib for treating severe rheumatoid arthritis - guidance (TA665)

Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer - guidance (TA668)

Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies - guidance (TA669)